Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
435
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia

Diana Abbotta Department of Public Health, University of Colorado, Aurora, CO, USA
,
Evan Cherryb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Maria Amayab Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Christine McMahonb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Marc Schwartzb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Amanda Wintersb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Jeffrey Schowinskyb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Craig T. Jordanb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Clayton Smithb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
,
Jonathan A. Gutmanb Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
&
Daniel A. Pollyeab Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USACorrespondence[email protected]
 show all
Pages 1466-1473 | Received 03 Dec 2020, Accepted 04 Dec 2020, Published online: 30 Dec 2020

References

  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926–957.
  • Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010;28(10):1766–1771.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96.
  • Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795–2804.
  • Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
  • Herold T, Rothenberg-Thurley M, Grunwald VV, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161–3172.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.